October 20, 2020

The Niche

Knoepfler lab stem cell blog

Paul Simmons

1 min read

Allan Robins of Viacyte (pictured at left–sorry for the fuzzy image) and Paul Simmons of Mesoblast presented this morning at the CIRM Grantee Meeting. Both talks were outstanding. Robins went first. He started by saying how Viacyte had a productive pre-IND meeting with the FDA last year. I believe a target for them is to have IND in Q1 of 2014 and hopefully move to the clinical trials soon after. I gotta say I love Viacyte’s technology. Having a frozen product that then can …Read More